Skip to content
Medical Health Aged Care, Women

The Christmas gift that keeps giving: The Australian Women’s Health Diary

Breast Cancer Trials 2 mins read

Angela was just 38 years old when she was diagnosed with breast cancer, while on a road trip around Australia. Forced to cut her dream tour with her husband short, she had surgery for stage 2 Luminal A breast cancer within a week of being diagnosed.

Julie was 43 when she was told she had hormone-sensitive, stage 3 breast cancer. Working full-time and caring for her two young children, her intensive schedule of chemotherapy, surgery and radiation was particularly tough in the midst of Covid lockdowns.

Wendy was diagnosed in April 2024, at age 63. With her daughter’s wedding imminent and upcoming travel plans laid, she was keen to get back to the life she’d planned as quickly as possible.

Unified by their breast cancer diagnoses, these three women have something else in common – they’re all featured in the 2026 Australian Women’s Health Diary, which raises vital funds for breast cancer research. 

In a convenient A5 size and with all the essential features, the diary is a resource of reliable health and wellbeing information, packed with motivational tips, diet, exercise, and skincare advice, a health checklist, budget planner, and more - perfect for that Christmas gift list. 

For 47 years, the work of Breast Cancer Trials has improved the treatment of breast cancer, led to changes in the way breast cancer is managed and has saved thousands of lives. 

Deaths from breast cancer have fallen 30% over the past 20 years, which is largely due to new treatments like Herceptin, Exemestane, Letrozole and Tamoxifen identified through the Breast Cancer Trials research program. However, more research is still needed. In Australia, 58 people are diagnosed with breast cancer each day and a further nine lose their lives to the disease.

“Our significant breakthroughs have been possible thanks to the support of the many Australians who buy the Australian Women’s Health Diary each year,” explained Ms Julie Callaghan, Chief Operating Officer – Fundraising and Philanthropy at Breast Cancer Trials. “But more research is urgently needed to ensure every person, with every type of breast cancer, gets the treatment they need. Support for this diary is a win-win – it’s the perfect organiser for you and a special gift for a loved one, and all proceeds support our clinical trials research to identify new treatments and prevention strategies.”

Priced at $19.99, the 2026 Australian Women’s Health Diary is available nationally from newsagents, selected Woolworths, participating Post Offices and online at www.womenshealthdiary.com.au.

 


About us:

Founded in 1978, Breast Cancer Trials conducts a multicentre national and international clinical trials research program into the treatment and prevention of breast cancer. Every breast cancer treatment available today has been proven through clinical trials research. More than 1,000 researchers in 118 institutions across Australia and New Zealand, together with the organisation’s donors, are committed to the vision of no more lives cut short.


Contact details:

Sara McGregor

Media & PR Lead

M: 0424 591 241

E: [email protected]    

Media

More from this category

  • Medical Health Aged Care
  • 22/01/2026
  • 23:11
Concept Medical Inc.

Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES

TAMPA, Fla.–BUSINESS WIRE– Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first…

  • Contains:
  • Medical Health Aged Care
  • 22/01/2026
  • 22:11
Sinovac Biotech Ltd.

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

BEIJING--BUSINESS WIRE-- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and…

  • Medical Health Aged Care
  • 22/01/2026
  • 17:11
Galderma

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.